IGFBP2表达评估idh突变的胶质瘤患者生存 （IGFBP2 expression predicts IDH-mutant glioma patient survival） ...

In the case of the enzyme, isocitrate dehydrogenase, the kinetic alterations of many orders of magnitude of the enzyme action are related to changes of a fraction of an angstrom of its amino acid ...

in patients with recurrent isocitrate dehydrogenase (IDH) mutant astrocytoma. The company was quick to note that while the STELLAR study (NCT02796261) missed its primary efficacy endpoint of ...

Rigel Pharmaceuticals has enrolled the first subject in a Phase I trial of its oral spleen tyrosine kinase (SYK) inhibitor, ...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) recently released its preliminary financial results for the fourth quarter and fiscal year ended December 31, 2024, as outlined in an 8-K filing with the ...